Improving Proteinuria Screening with Mailed Smartphone Urinalysis Testing in Previously Unscreened Patients with Hypertension: a Randomized Controlled Trial

Abstract

BackgroundProteinuria screening is recommended for patients with hypertension to screen for kidney disease and identify those at elevated risk for cardiovascular disease. However, screening rates among hypertensive patients are low. Home testing strategies may be useful in improving proteinuria screening adherence.MethodsWe conducted an individual-level, randomized trial at 55 primary care clinic sites in the Geisinger Health System to evaluate the effectiveness of a strategy using home smartphone urinalysis test (Dip.io) to complete proteinuria screening in previously unscreened non-diabetic patient portal users with hypertension. All patients received an educational letter and a standing urinalysis lab order, and then were randomized to control (usual care) or intervention. Intervention arm participants were invited to complete proteinuria screening with a mailed home smartphone urinalysis test. Co-primary outcomes were completion of proteinuria screening and number of albuminuria cases (albumin/creatinine ratio [ACR] ≥ 30 mg/g or protein/creatinine ratio ≥ 150 mg/g) at the end of 3 months. We also evaluated patient satisfaction with the home test, and compliance with recommendations for patients with newly detected albuminuria.ResultsA total of 999 patients were randomized to intervention or control. Out of 499 patients assigned to the intervention arm, 253 were reached by phone, and 69/97 (71.1%) consented patients completed the home test. Overall, the intervention increased proteinuria screening completion (28.9% vs. 18.0%; p<0.001) with no effect on the number of albuminuria cases (4 vs. 4) although only 6/57 (10.5%) patients with trace or 1+ urine dipstick protein had a follow-up quantitative test. Among the 55 patients who completed a survey after the home test, 89% preferred testing at home rather than the physician’s office.ConclusionsA strategy using a home urinalysis smartphone test increased proteinuria screening rates in previously unscreened patients with hypertension and may be useful in increasing rates of proteinuria screening compliance. Future studies are needed to determine whether improving early detection of kidney disease can improve future kidney health.Trial RegistrationClinical Trial Registry: NCT03470701https://clinicaltrials.gov/ct2/show/NCT03470701

Developing a Mobile App (iGAM) to Promote Gingival Health by Professional Monitoring of Dental Selfies: User-Centered Design Approach

“…Some apps are able to alert a patient to when they need further professional assistance. Other apps assist in the diagnosis of specific pathologies, such as an app that uses the image processing of urine tests to diagnose kidney disease [ 36 ] (Healthy.io). In dentistry, there are apps that show clinical procedures using 3D imagery [ 37 ] (eg, Lexi-DENTAL COMPLETE, Lexicomp).…”

Hospitalization Risk among Older Adults with Chronic Kidney Disease

“…Our findings expand on previous research which has focused on eGFR [22][23][24][25][26][27][28] by showing the added risk that is detectable with measured albuminuria, reinforcing KDIGO recommendations for measuring albuminuria to fully stage CKD. Although the United States Preventive Services Task Force (USPSTF) has found insufficient evidence to recommend screening for CKD in asymptomatic individuals [29] in many clinical settings, eGFR is known to be reduced and albuminuria measurement is recommended but not necessarily implemented [30][31][32]. The strong relationship between these markers and hospitalization risk suggests an opportunity for early intervention to reduce further hospitalizations and associated costs among older adults with suboptimal measures of eGFR and ACR.…”

DIABETES MELLITUS (DM): Um problema de saúde pública

“…A presença de albuminúria ou proteinúria pode ser útil na estratificação de risco para determinar quais pacientes podem se beneficiar do controle com medicamentos para pressão arterial que atuam na inibição do sistema renina-angiotensina-aldosterona e uso de estatinas (LEDDY et al, 2019).…”